While these issues are being sorted out, it remains an attractive hypothesis that if BRAF mutation itself is associated with an enhanced radiosensitivity to SRS, then the use of a lower marginal dose may decrease the risk of tumor hemorrhage without compromising LC in this group of patients. This evidence concerns the gene BRAF and neoplasm.